高原肺动脉高压的发病机制与药物治疗研究进展  

Research progress on the pathogenesis and pharmacological treatment of high altitude pulmonary hypertension

作　　者：叶祥琳 古丽胡玛 岳娇 杨海霞 魏正莲 刘清 陈瑶 罗佳 裴海峰 YE Xianglin;GULI Huma;YUE Jiao;YANG Haixia;WEI Zhenglian;LIU Qing;CHEN Yao;LUO Jia;PEI Haifeng(School of Clinical Medicine Southwest Medical University,Luzhou 646000,China;College of Medicine,Southwest Jiaotong University,Chengdu 610031,China;Department of Cardiology and Nephrology,950th Hospital of PLA,Yecheng 844900,Xinjiang,China;Department of Pediatrics,Chinese People’s Liberation Army Western War Zone General Hospital,Chengdu 610083,China;Department of medical engineering,the 950th Hospital of PLA,Yecheng 844900,Xinjiang,China;Nursing Department,the 950th Hospital of PLA,Yecheng 844900,Xinjiang,China)

机构地区：[1]西南医科大学临床医学院,四川泸州646000 [2]西南交通大学医学院,四川成都610031 [3]解放军第950医院心肾内科,新疆叶城844900 [4]西部战区总医院儿科,四川成都610083 [5]解放军第950医院医工科,新疆叶城844900 [6]解放军第950医院护理部,新疆叶城844900

出　　处：《暨南大学学报（自然科学与医学版）》2022年第5期467-479,共13页Journal of Jinan University(Natural Science & Medicine Edition)

基　　金：国家自然科学基金项目(81970241);西部战区总医院院管重点项目(2021-XZYG-A03)。

摘　　要：高原肺动脉高压(HAPH)是以低氧引起的肺血管收缩和肺血管重构为特征,在高原地区有高发病率与高致死率的病理综合征,其严重威胁着高原人群的身体健康,但该病的发病机制尚不明确。相关研究指出长期低氧刺激可通过血管重构、炎症反应、氧化应激与基因调控等途径共同促进肺动脉高压的发展。近年来,与HAPH相关的新的信号通路与药物不断涌现,明确HAPH的发病机制可为高原病的预防和治疗奠定基础。本文将对HAPH发病机制及相关药物研究进展进行介绍,以对相关疾病的治疗有所启示。High altitude pulmonary hypertension(HAPH)is a pathological syndrome characterised by pulmonary vasoconstriction and pulmonary vascular remodelling caused by hypoxia,with high morbidity and mortality rates in highland areas,posing a serious threat to the health of highlanders;however,the pathogenesis of this disease is still uncertain.Studies have shown that chronic hypoxic stimulation can contribute to the development of pulmonary arterial pressure through a combination of vascular remodelling,inflammatory responses,oxidative stress and gene regulation.In recent years,new signalling pathways and drugs associated with plateau pulmonary hypertension have emerged.In this paper,the pathogenesis of HAPH and related drug research progress are introduced to provide insight into the treatment of the related disease.

关 键 词：高原肺动脉高压 氧化应激 炎症反应 肺血管重构 肺动脉高压治疗 

分 类 号：R543.2[医药卫生—心血管疾病]